Raymond James Downgrades AMAG Pharmaceuticals (AMAG) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
AMAG Pharmaceuticals Provides Financial and Business Update
January 9, 2017 8:01 AM EST2016 total revenue increased 45 percent
Provides update on Makena® next-generation program
Anticipates 2017 GAAP revenue of $620-$670 million, including Makena net sales of $410-$440 million
WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today provided a business update, including announcing preliminary unaudited fourth quarter and annual 2016 financial results, 2017 financial guidance, and an update on its Makena® subcutaneous auto-injector program. In a separate release, the company also announced a licensing transaction for RekyndaTM (bremelanotide). The company will present further... More
AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder
January 9, 2017 8:00 AM ESTTwo Phase 3 trials completed for Rekynda; co-primary endpoints met
Will address underserved medical condition with significant untapped market potential
Broadens AMAGs presence in womens health and leverages AMAGs commercial capabilities and customer relationships
WALTHAM, Mass. and CRANBURY, N.J., Jan. 09, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) together with Palatin Technologies, Inc. (NYSE MKT: PTN) today announced they have entered into an agreement for exclusive North American rights to develop... More
